Press Releases

  • 20 July 2021

    Jubilant Ingrevia – Q1’FY22 Results*

    The Board of Jubilant Ingrevia Limited met today to approve financial results for the quarter ended June 30th, 2021.

    *Financial numbers for comparative periods are presented on Pro-forma basis to reflect continuing operations pre and post demerger as explained in Note 2 in the disclaimer.
    The Board of Jubilant Ingrevia Limited met today to approve financial results for the quarter ended June 30th, 2021.

    Commenting on the Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co- Chairman, Jubilant Ingrevia Limited said:

    “With immense pleasure I would like to announce that we have started the FY22 with a very positive note by delivering our record quarterly financial performance so far. Along with managing COVID-19 related challenges, we reported highest ever quarterly Revenue and EBITDA during Q1’FY22.

    In our Specialty Chemicals segment we witnessed strong growth across product segments. In Nutrition & Health Solution segment, the demand grew across geographies. In Life Science Chemical Segment, we witnessed favorable market conditions leading to strong demand and improved product contribution.

    The Input cost continued to rise throughout the quarter and businesses are trying to pass on the cost increases. During the quarter we also witnessed an all-time high price of Acetic Acid which was passed-on successfully.

    I am pleased to inform that company’s growth projects are progressing as per plan.

    With our continuous endeavor to reduce leverage, we have further reduced the net debt by Rs 45 Crore in Q1’FY22

    During Second wave of Covid, we created a focused task force across our business units and locations to support our employees and their families. The efforts of the task force resulted in significant mitigation of Covid hardship for our people. We also take this opportunity to thank all our employees who have worked tirelessly across all our plants and offices to ensure continuity in company’s operations, while continuing to serve our global customers”.

    Q1’FY22 Highlights

    A. Consolidated

    Segment Wise Analysis

    B. Speciality Chemicals

    • Specialty Chemicals revenue grew by 18% on YoY basis driven by higher volume across product segments.
    • North America revenue grew significantly; percentage share to total revenue increased to 9% from 5% in Q1’FY21.
    • Domestic consumption has gone up and percentage share to total revenue increased to 41% from 33% in Q1’FY21.
    • Domestic sales for export increased to 11% from 6% in Q1’FY21.
    • Pharma, Consumer, Nutrition and Industrial demand has gone up.
    • EBITDA grew by 22% YoY. Margin improved at 27.7% vs 26.8% in Q1’FY21, driven by higher volumes and prices

    C. Nutrition & Health Solutions

    • Nutrition and Health Solutions revenue grew by 13% on YoY basis.
    • Growth was driven by prices and growth in Niacinamide volume.
    • Animal Nutrition and Health solution business also grew led by strong volume growth contributed by Choline Chloride and specialty products.
    • Consumption in EU and Japan has gone up significantly, and contribution percentage to revenue increased to 36% from 24% in Q1’FY21.
    • Feed and Cosmetics demand has gone up on YoY basis
    • EBITDA de-grew by 15% on YoY basis. EBIDTA Margin stood at 15.9% vs 21.0% in Q1’FY21, EBITDA margin lower by 5.2% mainly on account of continuing increase in input costs and along with discontinuation of export benefit (MEIS).

    D. Life Science Chemicals Segment

    • Life Sciences Chemicals revenue grew by 103% on YoY basis
      • Life Sciences Chemical revenue growth was driven by higher volume as well as prices.
      • Prices improvement was mainly on account of favorable market condition driven by lower operating rates of Acetic Acid in US and rest of the world and also on account of increase in the input cost of Acetic Acid.
    • Consumption in domestic sales for export has gone up significantly and its contribution percentage to revenue increased to 22% from 18% in Q1’FY21
    • Demand across all industry segments have grown.
    • EBITDA Margin stood at 27.3% compared to 7.1% in Q1’FY21. Growth in EBITDA margin was driven by
      • Improved product contribution driven by favorable market condition and Acetic Acid stock led benefit due to increase in prices.
      • Witnessed operating leverage across all the Life Sciences Ingredients plants, that operated at more than 90% capacity utilization.

    E. Business Outlook

    • Our businesses remain strong and during the year we expect to deliver better performance over last year.
    • The Input prices continue to increase and the efforts to pass on the increase are being made continuously Our ongoing Diketene Capex is as per schedule, and it will be commissioned during the quarter Oct to Dec 2021
    • Further during the year, we are committing investment worth Rs. 360 Crore for following growth capex. At peak capacity these investments are expected to generate additional annual revenue of Rs. 900 Crore at prevailing prices
      • CDMO GMP Facility at Bharuch. (Expected to be in operation during the quarter April to June 2022)
      • Two Multi-Purpose plants of Speciality Chemicals. (Expected to be in operation during the quarter April to June 2022)
      • Food Grade Acetic Acid. (Expected to be in operation during the quarter April to June 2022)
      • Acetic Anhydride Plant. (Expected to be in operation during the quarter Jan to March 2023)
      • Agro Actives Phase-1. (Expected to be in operation during the quarter Jan to March 2023)
    • Our expected capex cash outflow for the year will be in the range of Rs 350 crore.
    • All figures are in Rs Crore unless otherwise stated
    • Q1’FY21 is derived from 3 month of discontinued operation of LSI segment of Jubilant Pharmova Limited on Pro-forma basis
    • EPS has been computed on combined profits assuming existence of share capital for full year.

    Earnings Call details

    The company will host earnings call at 5.00 PM IST on

    Participants can dial-in on the numbers below
     Primary Number: + 91 22 6280 1141 / + 91 22 7115 8042
     Local Access Number: +91-7045671221 (Available all over India)
     Toll Free Numbers:
    USA: 1 866 746 2133
    UK: 0 808 101 1573
    Singapore: 800 101 2045
    Hong Kong: 800 964 448

    Replay: July 20 to July 27, 2021
    Dial-in: +91 22 7194 5757/ +91 22 66635757
    Playback ID: 68835#

    About Jubilant Ingrevia Limited

    Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.
    The Company offers a broad portfolio of high quality ingredients that find application in a wide range of industries. The company has 2,100 employees and serves more than 1,400 customers in more than 50 countries across the world. The Company’s portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis.
    Jubilant Ingrevia is a Responsible Care certified company, driven by the motive to add value to millions of lives through innovations and cutting-edge technology. As a leader in key products that the Company manufactures, it takes pride in being a partner of choice for its valued customers.
    For more information, please visit: www.jubilantingrevia.com.

    For more information, please contact

    For Investors

    Hemant Bakhru | Pavleen Taneja Ph: +91-120 436 1002 | 21
    E-mail: hemant.bakhru@jubl.com
    pavleen.taneja@jubl.com

    Siddharth Rangnekar CDR India
    Ph: +91 22 6645 1209
    E-mail: siddharth@cdr-india.com

    For Media
    Sudhakar Safaya
    Ph: +91-120 436 1034
    E-mail: sudhakar.safaya@jubl.com


    Clayton Dsouza
    Madison Public Relations
    E-mail: clayton.dsouza@madisonpr.in
    Phone number: +91 9930011602

    Disclaimer:

    Note 1

    Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company’s filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

    Note 2:

    Effective 1st February 2021, Life Science Ingredients business of Jubilant Pharmova Limited (earlier Jubilant Life Sciences Limited) demerged to Jubilant Ingrevia Limited and post demerger the consolidated financial results of the Jubilant Ingrevia Limited for the quarter and the year ended 31 March 2021 comprised results only for two months of operations, starting from 1st February 2021.

    To provide the comprehensive picture of the operations of the Company on continuing basis the results for previous periods has been presented on Pro- forma basis by using relevant portion of the published results of LSI Segment - Jubilant Pharmova Limited on Pro-forma basis as Under:

     

    • Results Q1’FY21 has been derived on Pro-forma basis from the reported discontinued operations for LSI segment of Jubilant Pharmova Limited on Pro-forma basis.
    • As explained in the Financial Results presentation deck for Q’4 FY 21 we had earlier presented results for fully year FY 21 on Pro-forma basis by combining the results from 01 April 2020 to 31 January 2021 from the reported discontinued operations for LSI segment of Jubilant Pharmova Limited and Results from Feb 21 to March 21 from the Audited results of Jubilant Ingrevia Limited and results for Q4’FY21 on Pro- forma basis by combining the results for January 2021 from the reported discontinued operations for LSI segment of Jubilant Pharmova Limited and Results from Feb 21 to March 21 from the Audited results of Jubilant Ingrevia Limited
    • EPS for previous periods has been computed assuming existence of share capital throughout the period.
  • 07 June 2021

    JUBILANT INGREVIA – Q4* & FY21* RESULTS (PRO-FORMA2)

    The Board of Jubilant Ingrevia Limited met today to approve financial results for the quarter ended March 31st, 2021.

    *Financial numbers are on combined Pro-forma basis to reflect continuing operations pre and post demerger as explained in Note 1 & 2 in the disclaimer.

    The Board of Jubilant Ingrevia Limited met today to approve financial results for the quarter ended March 31st, 2021.

    Commenting on the Company's performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman, Jubilant Ingrevia Limited said:

    "We are glad to announce that we performed well during FY21. Despite the COVID-19 related challenges, we reported significant growth in our Revenue, EBITDA and PAT in FY21. All our sites remained operational throughout the pandemic and initiatives were taken to mitigate COVID-19 impacts. Supplies of raw material, availability of logistics were ensured for uninterrupted servicing of our customers and strict Covid protocols were followed at all our sites and offices for safety of our employees.

    We also take this opportunity to thank all our employees who have worked tirelessly across all our plants and offices to ensure continuity in company's operations, while continuing to serve our global customers.

    Demand scenario in all our business segments continue to be strong. Company has established strong levers of growth to deliver superior performance over the medium term.

    As communicated to you earlier during our last communication, all growth plans are going on track and our FY'22 capex investment is estimated to be in range of Rs 300-350 Crore. The team is continuing to work towards meeting the plans.

    The Company reduced its net debt by Rs 594 Crore during FY21 and expects to reduce it further over the coming year."

    Q4'FY21 Highlights (Pro-forma2)

    A. Consolidated

    Segment Wise Analysis

    B. Speciality Chemicals

    • Speciality Chemicals revenue grew driven by growth in Fine chemical and new CDMO projects
    • Specialty Ingredient, Fine chemicals and Crop Protection chemicals grew in double digits through strong volume growth, driven by demand from Pharma, Agri and Nutrition customers
    • EBITDA Margin were slightly lower, mainly on account of discontinuation of export benefit (MEIS)

    C. Nutrition & Health Solutions

    • Growth in Nutrition & Health Solutions Revenue was led by volume growth
    • Animal Nutrition and Health solution business also grew in double digits due to strong volume growth contributed by Choline Chloride and Specialty products
    • EBITDA margins were lower, mainly on account of discontinuation of export benefit (MEIS)

    D. Life Science Chemicals Segment

    • Life Sciences Ingredients grew by higher double digit on YoY basis
    • Life Sciences Chemical revenue grew in double digits, driven by favorable market condition from Pharma, Packaging Industrial application from domestic as well as export Geography
    • Increase in cost has been passed on through price increase

    E. Consolidated

    • Revenue growth was primarily driven by growth in volume and pricing together
    • Capex of Rs 122 Crore in FY21
    • Witnessed significant deleveraging, Gross debt reduced by Rs 747 Crore in FY21
    • Net debt reduced by Rs 594 Crore during FY21. Net Debt to EBIDTA now stands at less than 0.7x
    • ROCE stood at 20.2% and ROE at 16.4%

    Segment Wise Analysis

    F. Speciality Chemical Segment

    • EBITDA Margin stood higher because of better product mix and higher margin in CDMO projects
    • Specialty Ingredient, Fine chemicals and Crop Protection chemicals grew in higher single digit through strong volume growth driven by demand from Pharma, Agri and Nutrition customers
    • CDMO revenue grew by new projects of Pharma and Agro

    G. Nutrition & Health Solutions Segment

    • Nutrition and Health Ingredients business grew in double digit on YoY basis, driven by robust price growth from favorable market conditions
    • Animal Nutrition and Health solution business grew in double digit on YoY basis, driven by volume growth contributed by Choline Chloride and Specialty products

    H. Life Science Chemicals Segment

    • Revenue growth in Life Sciences Ingredients business is contributed by double digit volume growth of Acetic Anhydride from Pharma and Agro segment and higher price driven by favorable market condition
    • Acetic Acid price remained flat in FY'21 vs FY20 on full year basis
    • Specialty Ethanol grew by higher single digit on YoY basis, driven by higher volume growth in Pharma and Industrial Alcohol segment
    • Life Sciences Chemical segments EBITDA margin stood higher on account of improved operating leverage and higher price in domestic as well export markets

    I. Business Outlook

    • Demand scenario in all our business segments continue to be strong
    • Given the strong demand and new customer acquisition, we believe COVID-19 is not likely to have a material impact on our overall performance, provided the pandemic situation does not materially deteriorate going forward
    • Demand for our Speciality Chemicals and Nutrition and Health Solutions Segment continues to be stable. Our new project i.e. first phase of Diketene derivatives is on track
    • In our Life Science Chemicals business, Acetic Anhydride market situation continue to be favorable on account of higher demand and lower availability due to restricted production out-put in certain part of the world
    • As communicated during investor call in March'21, all our growth plans including new capex investments are on track and our FY'22 capex investment is estimated to be in range of Rs 300-350 Cr
    • During last year company has reduced the net debt by Rs.594 Cr. Company continues to focus on debt reduction.

    Income Statement – Q4 & FY21 (Pro-forma2)

    • All figures are in Rs Crore unless otherwise stated
    • -  Q4'FY21 is calculated from 1 month of discontinued operation of LSI segment of Jubilant Pharmova Limited and 2 months of Jubilant Ingrevia Limited

    -  Q4'FY20 is calculated from 3 month of discontinued operation of LSI segment of Jubilant Pharmova Limited

    -  FY21 is calculated from 10 month of discontinued operation of LSI segment of Jubilant Pharmova Limited and 2 months of Jubilant Ingrevia Limited

    -  FY20 is calculated from 12 month of discontinued operation of LSI segment of Jubilant Pharmova Limited

    -  EPS has been computed on combined profits assuming existence of share capital for full year.

    Earnings Call details

    The company will host earnings call at 5.00 PM IST on

    Participants can dial-in on the numbers below

    Primary Number: + 91 22 6280 1141 / + 91 22 7115 8042

    Local Access Number: +91-7045671221 (Available all over India)

    Toll Free Numbers:

    USA: 1 866 746 2133
    UK: 0 808 101 1573
    Singapore: 800 101 2045
    Hong Kong: 800 964 448
    Replay: February 07 to February 13, 2021
    Dial-in: +91 22 7194 5757/ +91 22 66635757
    Playback ID: 20733#

    About Jubilant Ingrevia Limited

    Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.

     The Company offers a broad portfolio of high quality ingredients that find application in a wide range of industries. The company has 2,100 employees and serves more than 1,400 customers in more than 50 countries across the world. The Company's portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis.

    Jubilant Ingrevia is a Responsible Care certified company, driven by the motive to add value to millions of lives through innovations and cutting-edge technology. As a leader in key products that the Company manufactures, it takes pride in being a partner of choice for its valued customers.

    For more information, please visit: www.jubilantingrevia.com.

    For more information, please contact:

    For Investors

    Hemant Bakhru | Pavleen Taneja

    Ph: +91-120 436 1002 | 21

    E-mail: hemant.bakhru@jubl.com

    pavleen.taneja@jubl.com

     

    Siddharth Rangnekar

    CDR India

    Ph: +91 22 6645 1209

    E-mail: siddharth@cdr-india.com

     

    For Media

    Sudhakar Safaya

    Ph: +91-120 436 1034

    E-mail: sudhakar.safaya@jubl.com

    Clayton Dsouza

    Madison Public Relations

    E-mail: clayton.dsouza@madisonpr.in

    Phone number: +91 9930011602

    Disclaimer

    Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

    Note 1:

    -  During the quarter and the year ended 31 March 2021, the consolidated financial results of Jubilant Ingrevia Limited comprises results only for two   

        months of operations, starting from 1st February 2021, being the effective date of demerger.

    -  To provide the comprehensive picture of the operations of the Company on continuing basis the results for FY21 and Q4'FY 21 has been presented by

        combining the relevant portion of the published results of LSI Segment - Jubilant Pharmova Limited and Jubilant Ingrevia Limited as Under:

    -  Results from 01 April 2020 to 31 January 2021 and previous year has been taken from the reported discontinued operations for LSI segment of Jubilant

        Pharmova Limited. 

    -  Results from Feb 21 to March 21 has been taken from the Audited results of Jubilant Ingrevia Limited.

    -  EPS has been computed on combined profits assuming existence of share capital throughout the year

    Note 2:

    -  Q4'FY21 is calculated from 1 month of discontinued operation of LSI segment of Jubilant Pharmova Limited and 2 months of Jubilant Ingrevia Limited

    -  Q4'FY20 is calculated from 3 month of discontinued operation of LSI segment of Jubilant Pharmova Limited

    -  FY21 is calculated from 10 month of discontinued operation of LSI segment of Jubilant Pharmova Limited and 2 months of Jubilant Ingrevia Limited

    -  FY20 is calculated from 12 month of discontinued operation of LSI segment of Jubilant Pharmova Limited

  • 31 March 2021

    Entries open for the 12th edition of the prestigious 'Social Entrepreneur of the Year (SEOY) - India Award 2021'

    Jubilant Bhartia Foundation and Schwab Foundation for Social Entrepreneurship, the sister organization of the World Economic Forum, announces the opening of entries for the 12th edition of the annual competition - Social Entrepreneur of the Year (SEOY) India Award 2021.

    Noida, March 31, 2021: Jubilant Bhartia Foundation and Schwab Foundation for Social Entrepreneurship, the sister organization of the World Economic Forum, announces the opening of entries for the 12th edition of the annual competition - Social Entrepreneur of the Year (SEOY) India Award 2021. In 2010 the Schwab Foundation for Social Entrepreneurship and Jubilant Bhartia Foundation joined hands to promote social innovation through the social entrepreneurship awards in India.

    • Social Innovation Takes Off in India: A total of over 1600 unique social innovation applications have been received in 11 years.
    • 11 years have seen a total of 523 women applications across India!
    • Women Change Makers: 7 out of 11 winners of the SEOY India award are women social entrepreneurs.
    • Turnover of participating social organisations range from Rs 1 million to Rs 600 million!
    • More stringent evaluation: Two new parameters for evaluation of social entrepreneurs – Market-based and Technology-enabled solutions added this year.
    • New Trends: In the recent years, sustainable farming and clean technology have emerged as new areas of social entrepreneurship

    The application entry for the Social Entrepreneur of the Year (SEOY) India Award 2021’ will be accepted till April 30, 2021. Interested candidates may submit the application form available at jubilantbhartiafoundation.com or can email the filled form to jbf_seoy@jubl.com

    The winner of the Social Entrepreneur of the Year (SEOY) India Award 2021 will be announced on October 7, 2021.

    The award recognizes individuals and organizations who implement innovative, sustainable, and scalable solutions to address pressing issues faced by under-served communities to make inclusive growth a reality in India. They work in diverse areas such as health, education, employment, water, clean energy, building identity & entitlements, financial literacy, access to information and technology among others.

    The participating individuals and organizations are evaluated on the key parameters of Market-based, Technology-enabled, Sustainability, Direct Social Impact, Reach & Scope, Replicability. The finalists will be selected following an intensive search and selection process, including expert reviews and site visits. The winner is selected by a prominent Jury consisting of eminent leaders and professionals from the Government, Business, Media, and Civil Society.

    The winner of SEOY India will join the world’s largest network of social enterprises affiliated with The Schwab Foundation for Social Entrepreneurship, to engage, build and sustain their social enterprises. The winner is awarded by a prominent chief guest in a magnificent ceremony every year.

    The Social Entrepreneur of the Year (SEOY) India Award aims to promote and celebrate leading social entrepreneurs and their unique ventures in India that help in addressing the various gaps in our society and country. Through providing recognition, the SEOY India Award hopes to inspire many other potential social entrepreneurs in India every year.

    About Schwab Foundation for Social Entrepreneurship was co-founded by Professor Klaus Schwab, Founder and Executive Chairman of the World Economic Forum, and his wife Hilde. For twenty years, the Schwab Foundation for Social Entrepreneurship has supported the world’s leading social entrepreneurs in their efforts to create a more just, equitable, and sustainable world. The Schwab Foundation provides unparalleled platforms at the regional and global level to highlight and advance leading models of sustainable social innovation. Learn about us at www.schwabfound.org and follow us on Twitter: https://twitter.com/schwabfound

    About Jubilant Bhartia Foundation (JBF), established in 2007, is the not-for-profit organisation of the Jubilant Bhartia Group. It focuses on conceptualising and implementing the Corporate Social Responsibility initiatives (CSR) for the Group. The Jubilant Bhartia Foundation’s activities include various community development work, healthcare programs, cultural and sports events, environmental preservation initiatives, vocational training, women empowerment, educational activities, and promotion of Social Entrepreneurship. www.jubilantbhartiafoundation.com

    Follow Jubilant Bhartia Foundation on:
    Twitter: @indiaseoy  
    Facebook: https://www.facebook.com/IndiaSEOY/

    Follow the Schwab Foundation for Social Entrepreneurship on:
    Twitter: https://twitter.com/schwabfound
    Facebook: https://www.facebook.com/schwabfound/

    For media queries:
    Vivek Prakash
    Jubilant Bhartia Foundation
    Phone: +91-9810674758
    E-mail: vivek.prakash@jubl.com

We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyse traffic. If you continue to use this site we will assume your acceptance.